Please assess the completion status of the following clinical trial:

Trial Title: CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of diffuse large B cell Non-Hodgkin's lymphoma with characteristic immunophenotypic profile~* Patient has not received any prior anti-cancer therapy for lymphoma~* Tumor tissue confirmed to express the cluster of differentiation antigen 20 antigen by flow cytometry or immunohistochemistry~* Measurable disease as defined by a tumor mass of 1cm or greater in one dimension~* Stage II (abdominal-not radiotherapy appropriate), III, or IV disease~* Age \> 18 years~* Performance Status of 0-2~* Laboratory parameters as outlined in protocol~* Patient agrees to use birth control~Exclusion Criteria:~* Known central nervous system involvement by lymphoma~* Serious uncontrolled concurrent illness such as active coronary artery disease, severe lung disease, heart failure, active alcohol abuse, active concurrent malignancy except non-melanoma skin cancer or carcinoma in situ of the cervix~* Any evidence of prior natural exposure to Hepatitis B~* Active rheumatologic disease which may be exacerbated by GM-CSF~* Cardiac ejection fraction less than 45%~* Known HIV disease~* Patient is pregnant or nursing~* Patient is receiving other investigational drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GMCSF-RCHOP (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).